Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TERT | O14746 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489665 | 0.88 | MEN1 (0.60) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL3263155 | 0.87 | LMNA (0.72) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL8877644 | 0.85 | LMNA (0.62) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL11117696 | 0.82 | PKM (0.47) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL28419773 | 0.82 | MEN1 (0.59) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL23137230 | 0.81 | LMNA (0.66) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL24700466 | 0.81 | LMNA (0.66) | MEN1KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL6501165 | 0.81 | ALDH1A1 (0.80) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL28427660 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2ALMNAHPGDGSK3B | |
| SCHEMBL30901790 | 0.79 | PTGS2 (0.57) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894054-B2 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. (US) | 2005-05-17 | — | — | US | claimed |
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | claimed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | claimed |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | MASSACHUSETTS GENERAL HOSPITAL | 2020-05-07 | — | — | US | disclosed |
| US-10301294-B2 | Compounds for the treatment of tuberculosis | The Broad Institute Inc. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | NIH - DEITR | 2016-02-04 | — | — | US | disclosed |
| WO-2014165090-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-6894054-B2 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1357913-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | TELIK, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002064135-A1 | HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 | TELIK, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301294-B2 | Compounds for the treatment of tuberculosis | GOT2, G6PD, FNTB | MEN1 3612/4885KMT2A 3963/4885LMNA 1820/4885 |
| US-20200140425-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | MEN1 3612/4885KMT2A 3963/4885LMNA 1820/4885 |
| US-20160031870-A1 | COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GOT2, G6PD, FNTB | MEN1 3612/4885KMT2A 3963/4885LMNA 1820/4885 |
| US-20030073726-A1 | Heterocyclic inhibitors of glycine transporter 2 | SLC1A2, SLC1A1, SLC1A3 | MEN1 2373/4885KMT2A 1157/4885LMNA 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.